Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211010005020/en/ Mari Scheiffele (Photo: Business Wire) Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Mari Scheiffele ...
The following slide deck was published by Ipsen S.A. in conjunction with this event. For further details see: Ipsen S.A. (IPSEY) Investor Presentation - Slideshow
Mirati Therapeutics (MRTX +4.9%) has reached a four-month high amid a series of catalysts, including the appointment of the industry veteran David Meek as the new CEO. Mr. Meek will assume duties as the CEO and will join the company board effective immediately, Mirati (NASDAQ:MRTX) said ...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced presentation of new analyses at the European Society for Medical Oncology (ESMO) Congress 2021 across different forms of cancer for people treated with Cabometyx ® (cabozantinib). Of note, the final analysis of ...
Ipsen’s submission for extension of indication for Cabometyx ® (cabozantinib) based on data from the COSMIC-311 trial received validation from the European Medicines Agency in August 2021 Separate follow-up data presented at the European Society for Medical Oncolog...
Shares of specialty pharmaceutical company Endo International (ENDP) have plunged in price over the past month owing to news that the drugmaker is evaluating financial restructuring options to deal with several opioid-related lawsuits. So, although the company remains committed to expanding i...
The world’s premier biopharmaceutical company Pfizer’s (PFE) COVID-19 vaccine approval by the FDA marked a breakthrough achievement in the world’s battle with the COVID-19 pandemic. As the company prepares to roll out booster doses, it is well-positioned to see strong sal...
This follows ongoing dialogue with the U.S. FDA regarding the palovarotene NDA review, initiated in May 2021 Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) today announced, following very re...
Ipsen (OTCPK:IPSEY) and Exicure have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington’s disease (HD) and Angelman syndrome. Under the agreement, Ipsen will rec...
Ipsen obtains exclusive options to Spherical Nucleic Acids (SNAs™) currently under discovery evaluation for Huntington’s disease and Angelman syndrome Exicure will be responsible for discovery and certain pre-clinical development activities. In the event Ipsen exerci...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...